Abstract
Abstract
Purpose
This paper analyses the feasibility of tracking data originality for pharmaceutical manufacturing in a tamper-proof manner using a geographically distributed system. The main research question is whether it is possible to ensure the traceability of drug manufacturing through the use of smart contracts and a private blockchain network.
Methods
This work employs a private Ethereum network with a proof-of-authority consensus algorithm to allow participating nodes to commit the medicament manufacturing originality as transactions in blocks. We use smart contracts to assess the “Original” principle of the ALCOA+ data integrity principles for full sensor-enabled production lines within pharmaceutical manufacturing plants. We have evaluated our data originality assessment approach employing a temporal series of 1300 reports generated based on real datasets from pharma production lines. Out of these reports, 300 reports have been randomly tampered with to make them “unoriginal” (i.e., falsified).
Results
Evaluation consistently shows that the proposed approach systematically detects all the manufacturing records whether original or not, together with any source of falsification. By randomly injecting four common data falsification types, their approach effectively detects tampering and ensures the authenticity of the data originality acquired by sensors within manufacturing lines.
Conclusion
The approach of using a private blockchain network with a proof-of-authority consensus algorithm and smart contracts is a feasible method to track data originality for pharmaceutical manufacturing in a tamper-proof manner. In addition, this approach effectively detects tampering and ensures the authenticity of the data originality acquired by sensors within manufacturing lines.
Funder
Agencia Estatal de Investigación
Universitat Politècnica de València
Publisher
Springer Science and Business Media LLC
Subject
Drug Discovery,Pharmaceutical Science
Reference40 articles.
1. European Parliament–Council of the European Union, Directive 2011/62/EU of the European Parliament and of the Council of 8 June 2011 amending Directive 2001/83/EC on the Community code relating to medicinal products for human use, as regards the prevention of the entry into the legal supply chain of falsified medicinal products, Official Journal of the European Union 54 (2011) Document 32011L0062. http://dx.doi.org/10.3000/17252555.L_2011.174.eng.
2. McManus D, Naughton BD. A systematic review of substandard, falsified, unlicensed and unregistered medicine sampling studies: a focus on context, prevalence, and quality. BMJ Glob Health. 2020;5(8):e002393. https://doi.org/10.1136/bmjgh-2020-002393.
3. Rahman MS, Yoshida N, Tsuboi H, Tomizu N, et al. The health consequences of falsified medicines - a study of the published literature. Trop Med Int Health. 2018;23(12):1294–303. https://doi.org/10.1111/tmi.13161.
4. Attaran A, et al. How to achieve international action on falsified and substandard medicines. BMJ. 2012;345:e7381. https://doi.org/10.1136/bmj.e7381.
5. Mackey TK, Nayyar G. A review of existing and emerging digital technologies to combat the global trade in fake medicines. Expert Opin Drug Saf. 2017;16(5):587–602. https://doi.org/10.1080/14740338.2017.1313227.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献